To read the entire article for FREE, click here.
Editor’s Note: Most researchers and Lyme-literate doctors believe that so-called post-treatment Lyme disease syndrome is really due to the presence of ongoing infection in the body. However, it is also believed by some that Lyme can create ongoing overactive immunity, even after the infections have been cleared.
Subscribe to the World's Most Popular Newsletter (it's free!)
Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET
The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to overactive immunity including aberrant activity of the brain’s resident immune cells, microglia. Here we used [11C]DPA-713 and positron emission tomography to quantify the 18 kDa translocator protein, a marker of activated microglia or reactive astrocytes, in the brains of patients with post-treatment Lyme disease symptoms of any duration compared to healthy controls. Genotyping for the TSPO rs6971 polymorphism was completed, and individuals with the rare, low affinity binding genotype were excluded. Data from eight brain regions demonstrated higher [11C]DPA-713 binding in 12 patients relative to 19 controls. [11C]DPA-713 PET is a promising tool to study cerebral glial activation in PTLDS and its link to cognitive symptoms.
Source: By Coughlin JM1,2, Yang T3, Rebman AW3, Bechtold KT4, Du Y2, Mathews WB2, Lesniak WG2, Mihm EA3, Frey SM2, Marshall ES2, Rosenthal HB2, Reekie TA5, Kassiou M5, Dannals RF2, Soloski MJ3, Aucott JN6,7, Pomper MG8,9,10. Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. J Neuroinflammation. 2018 Dec 19;15(1):346. doi: 10.1186/s12974-018-1381-4